HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
A4062 Nivatrotamab (Anti-CD3 & GD2) Nivatrotamab is a humanized bispecific antibody targeting GD2 on tumor cells and CD3 on T cells to enhance immune activation. It is being developed for the treatment of metastatic small cell lung cancer (SCLC) by recruiting T cells to attack tumors. M. W 200.96 kDa Mar 09 2025
A4063 Ubamatamab (Anti-CA125 & CD3) Ubamatamab is a bispecific IgG4-based antibody targeting MUC16 on tumor cells and CD3 on T cells to enhance immune activation. It is designed for the treatment of ovarian cancer by recruiting T cells for MUC16-directed tumor cell killing with reduced Fcγ receptor affinity. M.W 144.64 kDa Mar 09 2025
A4064 Vanucizumab (Anti-Angiopoietin 2 & VEGF) Vanucizumab is a humanized bispecific IgG1 antibody targeting VEGF-A and Ang-2 to inhibit tumor angiogenesis. It is being developed for the treatment of advanced solid tumors demonstrating anti-tumor, anti-angiogenic, and anti-metastatic effects. M.W 146.89 kDa Mar 09 2025
A4066 Vudalimab (Anti-CTLA4 & PD-1) Vudalimab is a bispecific antibody targeting PD-1 and CTLA-4 to inhibit immune checkpoint regulation and enhance immune responses. It is being developed for the treatment of advanced malignancies by promoting T-cell activation against tumors and metastatic castration-resistant prostate cancer (mCRPC). M.W 125.43 kDa Mar 09 2025
A4067 Zenocutuzumab (Anti-HER2 & HER3) Zenocutuzumab is a humanized bispecific IgG1 antibody targeting HER2 and HER3 to enhance antibody-dependent cellular cytotoxicity (ADCC) and inhibit tumor growth. It is being developed for the treatment of cancers overexpressing HER2 and HER3, leveraging dual targeting for enhanced antitumor activity. M. W 145.88 kDa Mar 09 2025
A4068 Lomvastomig (Anti-PD-1 & TIM-3) Lomvastomig is a bispecific antibody targeting both PD-1 and TIM-3 to inhibit immune checkpoint regulation and enhance immune responses. It is designed to treat cancers by promoting T-cell activation and overcoming immune suppression. M.W 145.34 kDa Mar 09 2025
A4070 M701 (Anti-CD3 & EpCAM) M701 is a bispecific antibody targeting CD3 on T-cells and EpCAM on tumor cells to stimulate T-cell-mediated tumor cell death. It is being developed for the treatment of malignant ascites by redirecting T-cells to EpCAM-expressing tumors. M.W 125.84 kDa Mar 09 2025
A4071 Regn5678 (Anti-CD28 & PSMA) REGN5678 is a bispecific antibody targeting both PSMA on prostate cancer cells and CD28 on T-cells to enhance immune activation. It is being developed for the treatment of prostate cancer by redirecting T-cells to PSMA-expressing tumors, promoting tumor cell death. M.W 145.86 kDa Mar 09 2025
A4072 Flotetuzumab (Anti-CD3 & CD123) Flotetuzumab is a bispecific DART antibody targeting CD123 on tumor cells and CD3ε on T-cells to stimulate immune cell-mediated tumor lysis. It is being developed for the treatment of hematological malignancies by enhancing T-cell responses against CD123-expressing tumors. M.W 58.91 kDa Mar 09 2025
E5819 Clozapine N-oxide dihydrochloride Clozapine N-oxide dihydrochloride is a primary metabolite of clozapine. It acts as an agonist for human muscarinic designer receptors DREADD, with a pEC50 of 8.31 for the M1 DREADD. Mar 06 2025
A4005 Erfonrilimab (Anti-CTLA4 & PD-L1) Erfonrilimab is a humanized bispecific monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. It is used to treat solid tumors and exhibits promising efficacy in advanced non-small cell lung cancer (NSCLC) patients who had experienced failure or intolerance to prior platinum-based chemotherapy. MW: 107.44 KD. Mar 04 2025
E4640 Oditrasertib Oditrasertib (DNL-788, SAR 443820) is a first-in-class, selective, orally bioavailable, brain penetrant inhibitor of Receptor-interacting serine/threonine protein kinase 1 (RIPK1). It can be used in research of myotrophic lateral sclerosis and multiple sclerosis. Mar 03 2025
E4642 CVN293 CVN293 is a potent, selective, and brain permeable small-molecule inhibitor of potassium (K+) ion channel KCNK13 with an IC50s of 49 nM and 28 nM for hKCNK13 and mKCNK13, respectively. It also inhibits NOD-like receptor protein 3 (NLRP3) inflammasome-mediated IL-1ß production in LPS-stimulated primary neonatal murine microglia with an IC50 of 24 nM and has potential applications in Alzheimer’s disease research. Mar 03 2025
E5818 Fedratinib hydrochloride hydrate Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate, SAR 302503 hydrochloride hydrate) is a small-molecule, ATP-competitive inhibitor of JAK2 with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. It induces cancer cell apoptosis and has potential for efficacious treatment of JAK2V617F-associated myeloproliferative disease. Mar 03 2025
E4784 STL127705 STL127705 is a potent small molecule inhibitor of Ku70/80 heterodimer protein with an IC50 of 3.5 μM. It disrupts Non-Homologous End-Joining (NHEJ) by preventing DNA binding and inhibiting DNA-PKCS activation. It exhibits anticancer activity by inducing apoptosis and inhibiting cell proliferation. Mar 03 2025
A4001 Tibulizumab (Anti-BAFF & IL-17) Tibulizumab (LY3090106) is a tetravalent bispecific antibody which potently inhibits both B cell activating factor (BAFF), also known as CD257 and interleukin-17A (IL-17). It is used for the treatment of autoimmune diseases. MW: 201.44 KD. Mar 03 2025
E5786 SB 202190 hydrochloride SB 202190 hydrochloride is a selective inhibitor of p38 MAP kinase with IC50 values of 50 nM for p38α and 100 nM for p38β2. It exhibits anti-cancer activity, induces autophagy, and is studied for its role in hippocampus-dependent spatial memory and apoptotic regulation under chronic ischemia. Feb 27 2025
E5844 NSC2805 NSC2805 is a potent inhibitor of WWP2 ubiquitin ligase with an IC50 of 0.38 μM. It is used in cancer research for studying WWP2-associated pathways. Feb 27 2025
E4783 DiI DiI (DiIC18(3)) is a lipid-soluble fluorescent dye that traces neuronal pathways through retrograde and anterograde transport in neurons. It labels cell bodies, axons, dendrites, and dendritic spines, offering high brightness, slow fading, and long-lasting persistence without leakage. It is employed to investigate brain connectivity, including in postmortem human brain tissue. Feb 26 2025
A2169 Anti-mouse MHC Class II (I-A/I-E)-InVivo Anti-mouse MHC Class II (I-A/I-E)-InVivo reacts with mouse MHC Class II haplotypes I-Ab, I-Ad, I-Aq, I-Ed, and I-Ek. The antibody does not react with I-Af, I-Ak, or I-As haplotypes. The M5/114 antibody is reported to inhibit I-A-restricted T cell responses. Feb 25 2025